NGF Blog

Back

Gain Therapeutics Announces Issuance of Two New PCT Patents Covering GBA and GALC Modulator Compounds for Treatment of CNS Disorders

Activity of GBA and GALC Enzymes Play Key Roles in the Neurodegenerative Diseases and Lysosomal Storage Diseases

Bethesda MD., June 10th, 2021 (GLOBE NEWSWIRE) – Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by identifying and optimizing allosteric binding sites that have never before been targeted, today announced the publication of two PCT patents. PCT/IB2020/061158 and PCT/IB2020/0611156 are directed at compounds targeting misfolded beta-glucocerebrosidase (GBA) and galactosylceramidase (GALC) respectively, addressing central nervous system (CNS) and demyelinating disorders such as Parkinson’s Disease, Lewy body dementia and Alzheimer’s.


“This is a pivotal milestone for Gain Therapeutics as these two patents highlight the association between the approach to treating rare diseases, such as Gaucher Disease and Krabbe Disease, and the approach to treating more widely prevalent and growing disease states like Parkinson’s Disease and Multiple Sclerosis,” said Eric Richman, Chief Executive Officer of Gain. “The two issued patents reflect our focus and commitment to developing first in class therapies for these CNS and lysosomal storage diseases, and we are excited to strengthen our intellectual property and advance our potential to treat patients with these devastating diseases.”

PCT/IB2020/061158 covers compounds and therapeutic uses of conditions associated with the alteration of Beta-glucocerebrosidase (GBA). These conditions include Gaucher Disease, Parkinson’s Disease, and other Lewy body disorders including Alzheimer’s Disease and amyotrophic lateral sclerosis (ALS).

Read the full press release

Living a Better Today

Skip to content
Become a NGF Stepping Stones Sustainer